SC
CYCN icon

Sawyer & Company’s Cyclerion Therapeutics CYCN Stock Holding History

Sawyer & Company’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-205
Closed -$5K – 173
2022
Q1 		$5K Hold
205
– – ﹤0.01% 162
2021
Q4 		$7K Hold
205
– – ﹤0.01% 165
2021
Q3 		$13K Hold
205
– – 0.01% 163
2021
Q2 		$16K Hold
205
– – 0.01% 149
2021
Q1 		$11K Hold
205
– – 0.01% 148
2020
Q4 		$13K Hold
205
– – 0.01% 140
2020
Q3 		$25K Hold
205
– – 0.01% 131
2020
Q2 		$24K Hold
205
– – 0.01% 136
2020
Q1 		$11K Hold
205
– – 0.01% 144
2019
Q4 		$11K Hold
205
– – 0.01% 157
2019
Q3 		$50K Hold
205
– – 0.04% 119
2019
Q2 		$47K Buy
+205
New +$58K 0.03% 125

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Sawyer & Company's CYCN Position: Q2 2022 in Review

Sawyer & Company sold out of Cyclerion Therapeutics (CYCN) in Q2 2022, closing a stake of 205 shares — an estimated $5K sold.

Sawyer & Company first reported a position in CYCN in Q2 2019 and held it in 12 quarters. The position peaked at $50K in Q3 2019. 41 funds tracked by Wall St. Rank hold CYCN as of Q2 2022.

  • Sawyer & Company reported no remaining Cyclerion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sawyer & Company sold 205 Cyclerion Therapeutics shares in Q2 2022, an estimated $5K.
  • Sawyer & Company first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 12 quarters.
  • Sawyer & Company's Cyclerion Therapeutics position peaked at $50K in Q3 2019.
  • 41 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2022.

Based on Sawyer & Company's 13F filing for Q2 2022, filed 20 Jul 2022.